A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Evolocumab (REPATHA)

Evolocumab dramatically lowers LDL cholesterol by blocking the PCSK9 protein.

First FDA approval2018-10-09
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3.25B in CY2024 Part D spend3.7M claims · 931K beneficiaries · 329 plans surveyed

Lowest NADAC
$281.24/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$281.60
Across all dosage forms in distribution.
Highest NADAC
$281.95
Range is tight.
Plans with PA
509 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Evolocumab used for?

Evolocumab dramatically lowers LDL cholesterol by blocking the PCSK9 protein.

Is there a generic for Evolocumab?

No. Evolocumab is brand-only with no generic equivalents currently in market.

How much does my plan pay for Evolocumab?

Across 329 Part D plans, Evolocumab averages $281.60/unit (NADAC). Lowest available: $281.24/unit. Highest in distribution: $281.95/unit.

Is Evolocumab on the FDA shortage list?

No. Evolocumab is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

PCSK9 Inhibitor1 alternative in D1
01
Alirocumab
Brand: Praluent
$258.06Lowest NADAC
0Generic mfrs
$494.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.